Recently, FDA issued a new draft guidance on process validation. When finalized, it will supercede the previously issued guidance documents on process validation. It is expected that the final guidance will not be much different from the draft. This guidance document contains several statements that make it clear that statistical procedures will be expected. Some of these procedures are of an advanced nature and companies need to be prepared to meet these requirements.
Areas Covered in the Session:
Who Will Benefit: